EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Current Evidence and Directions for Intermittent Fasting During Cancer Chemotherapy

Kelsey Gabel, Kate Cares, Krista Varady, Vijayakrishna Gadi, Lisa Tussing-Humphreys

Advances in Nutrition · 2022

DOI: 10.1093/advances/nmab132 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advances in Nutrition, 2022. Verfasst von Kelsey Gabel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, USA. Electronic address: kdipma2@uic.edu. Hauptthemen laut MEDLINE: Obesity, Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIDDK NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Almost 40% of the adult population in the USA will be diagnosed with cancer in their lifetime. Diet is a modifiable factor which is known to affect cancer risk and recurrence. Yet, little is known about how diet influences cancer treatment outcomes. Intermittent fasting, characterized by periods of abstaining from foods and beverages alternated with periods of ad libitum intake, when adopted in the context of chemotherapy, has shown promise in preclinical models resulting in decreased vomiting, diarrhea, visible discomfort, and improved insulin sensitivity and efficacy of chemotherapeutic treatment. Although intermittent fasting during receipt of chemotherapy has been well-established in preclinical models, limited numbers of human studies are now being reported. This review aims to survey the current data examining the effect of intermittent fasting on chemotherapy efficacy, patient treatment outcomes, patient centered outcomes, and circulating biomarkers associated with cancer. Available data show that periodic fasting, a form of intermittent fasting, may hold potential to improve the effectiveness of chemotherapy, decrease treatment-related side effects and cancer-promoting factors such as insulin, while ameliorating treatment-related decreases in quality of life and daily functioning. Larger controlled periodic fasting trials, including exploration of alternate forms of intermittent fasting, are needed to better elucidate the effect of intermittent fasting on treatment and patient outcomes during chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityNeoplasmsAdultHumansIntermittent FastingQuality of LifeFastingDiet

Stichwörter der Autor:innen

cancerchemotherapyfasting mimicking dietintermittent fastingshort-term fasting

Autor:innen und Institutionen

  • Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, USA. Electronic address: kdipma2@uic.edu.
  • Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, USA.
  • Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA; University of Illinois Cancer Center, Chicago, IL, USA.
  • Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, USA; University of Illinois Cancer Center, Chicago, IL, USA.

Förderung

  • NCI NIH HHS
  • NIDDK NIH HHS
  • NIH

Zitieren

APA

Gabel, K., Cares, K., Varady, K., Gadi, V., & Tussing-Humphreys, L. (2022). Current Evidence and Directions for Intermittent Fasting During Cancer Chemotherapy. Advances in Nutrition. https://doi.org/10.1093/advances/nmab132

Vancouver

Gabel K, Cares K, Varady K, Gadi V, Tussing-Humphreys L. Current Evidence and Directions for Intermittent Fasting During Cancer Chemotherapy. Advances in Nutrition. 2022. doi:10.1093/advances/nmab132

BibTeX
@article{Gabel2022,
  author = {Gabel, Kelsey and Cares, Kate and Varady, Krista and Gadi, Vijayakrishna and Tussing-Humphreys, Lisa},
  title = {Current Evidence and Directions for Intermittent Fasting During Cancer Chemotherapy},
  journal = {Advances in Nutrition},
  year = {2022},
  doi = {10.1093/advances/nmab132}
}
Kostenlos starten →